REGENERON PHARMACEUTICALS, INC. Deferred Revenue 2009-2026 | REGN
What is deferred revenue?
Deferred revenue represents payments received in advance for goods or services that have not yet been delivered to customers.
What is REGENERON PHARMACEUTICALS, INC.'s current deferred revenue?
REGENERON PHARMACEUTICALS, INC. (REGN) annual deferred revenue for 2025 was $553.0M, a 11.90% decline from 2024. REGENERON PHARMACEUTICALS, INC. deferred revenue for the quarter ending March 31, 2026 was $636.2M.
What was REGENERON PHARMACEUTICALS, INC.'s deferred revenue in 2024?
REGENERON PHARMACEUTICALS, INC. annual deferred revenue for 2024 was $627.7M, a 36.78% increase from 2023.
What was REGENERON PHARMACEUTICALS, INC.'s deferred revenue in 2023?
REGENERON PHARMACEUTICALS, INC. annual deferred revenue for 2023 was $458.9M, a 3.98% decline from 2022.
What is REGENERON PHARMACEUTICALS, INC.'s 5-year deferred revenue CAGR?
REGENERON PHARMACEUTICALS, INC. deferred revenue grew at a compound annual growth rate (CAGR) of 0.87% from FY2020 to FY2025, going from $577.7M to $553.0M over 5 years.
Year-over-year comparison from 10-K annual reports
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $553.0M | -11.9% | 10-K |
| FY2024 | $627.7M | +36.8% | 10-K |
| FY2023 | $458.9M | -4.0% | 10-K |
| FY2022 | $477.9M | +8.1% | 10-K |
| FY2021 | $442.0M | -23.5% | 10-K |
| FY2020 | $577.7M | -2.4% | 10-K |
| FY2019 | $591.7M | +30.8% | 10-K |
| FY2018 | $452.5M | +217.8% | 10-K |
| FY2017 | $142.4M | -38.5% | 10-K |
| FY2016 | $231.7M | +50.9% | 10-K |
| FY2015 | $153.5M | +107.3% | 10-K |
| FY2014 | $74.0M | +57.5% | 10-K |
| FY2013 | $47.0M | -7.5% | 10-K |
| FY2012 | $50.8M | -1.6% | 10-K |
| FY2011 | $51.6M | -5.6% | 10-K |
| FY2010 | $54.7M | +102.5% | 10-K |
| FY2009 | $27.0M | - | 10-K |